Table 2.

The incidence of expression of CCL5, ER-α, ER-β, PR, and ErbB2 in breast tumor cells as detected by immunohistochemistry in biopsies of breast cancer patients diagnosed in stages I or II of disease

Disease freeProgressedProgressed/total (%)
Stage I
    CCL5+111212/23 (52)
    CCL5151515/30 (50)
    ER-α+141414/28 (50)
    ER-α121313/25 (52)
    ER-β+212222/43 (51)
    ER-β444/8 (50)
    PR+161313/29 (45)
    PR101414/24 (58)
    ErbB2+41111/15 (73)
    ErbB2221616/38 (42)
Stage II
    CCL5+92929/38 (76)
    CCL5252626/51 (51)
    ER-α+272828/55 (51)
    ER-α72727/34 (79)
    ER-β+253737/62 (60)
    ER-β-81818/26 (69)
    PR+242424/48 (50)
    PR103131/41 (76)
    ErbB2+71515/22 (68)
    ErbB2274040/67 (60)